With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
New acetabular system enhances precision, stability and robotic compatibility in total hip arthroplasty
New home-use glucometer delivers results in under 10 seconds with simplified testing, large memory storage, and user-friendly design
Hyderabad based 400-bed facility brings AI-driven care, advanced imaging, and integrated clinical systems under one roof
The product is manufactured at AKUMS’ state-of-the-art injectable facility in Kotdwar, Uttarakhand
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
_256_384.png){kind=logo}
New plan integrates critical illness protection, market-linked health fund and preventive care platform for holistic financial and health security
Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies
Subscribe To Our Newsletter & Stay Updated
